What’s the current market cap for Sabra Health Care REIT stock?

Sabra Health Care REIT (SBRA) has a market cap of $4.7bn as of June 17, 2026.

What is the P/E ratio for Sabra Health Care REIT stock?

The price to earnings (P/E) ratio for Sabra Health Care REIT (SBRA) stock is 29.45 as of June 17, 2026.

Does Sabra Health Care REIT stock pay dividends?

Yes, the Sabra Health Care REIT (SBRA) stock pays dividends to shareholders. As of June 17, 2026, the dividend rate is $1.2 and the yield is 6.47%. Sabra Health Care REIT has a payout ratio of 188.1% on a trailing twelve-month basis.

When is the next Sabra Health Care REIT dividend payment date?

The next Sabra Health Care REIT (SBRA) dividend payment date is unconfirmed.

What is the beta indicator for Sabra Health Care REIT?

Sabra Health Care REIT (SBRA) has a beta rating of 0.65. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Sabra Health Care REIT stock | $SBRA Share Price

13:30

15:10

16:45

18:25

20:00

About Sabra Health Care REIT

Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.

Ticker

$SBRA

Sector

Real Estate

Primary listing

NASDAQ

Employees

Headquarters

Tustin, United States

Website

www.sabrahealth.com

SBRA Metrics

BasicAdvanced

$4.7bn

29.45

$0.63

0.65

$1.20

6.47%

Bulls say / Bears say

Same-store managed senior housing cash NOI increased 17.1% year-over-year in Q2 2025, reflecting substantial operational improvement throughout Sabra’s core properties (Reuters).

Sabra secured a $500 million unsecured term loan in Q2 2025 to refinance $500 million in senior notes, enhancing liquidity and lowering both near-term maturity and interest rate exposure (Reuters).

Analyst sentiment remains positive, with a median 12-month price target of $20.00 implying 8.6% potential upside, and no sell ratings as of Q2, suggesting widespread market confidence (Reuters).

Same-store core revenue growth of 1.6% year-over-year in Q1 2026 lagged behind a 5.7% rise in core operating expenses, resulting in a 0.3% drop in same-store NOI and indicating margin pressure (https://s28.q4cdn.com/264003623/files/doc_earnings/2026/q1/supplemental-info/Q1-2026-Supplemental_FINAL.pdf).

For 15 Senior Housing Operating Portfolio properties on a same-store basis in Q1 2026, revenue increased just 0.8%, with a 4.8% gain in RevPOR offset by a 340 basis-point decrease in occupancy to 85.8%, leading to a 2.4% fall in same-store SHOP NOI and greater operational volatility (https://s205.q4cdn.com/302521515/files/doc_earnings/2026/q1/presentation/Business-Update-Q126.pdf).

Net debt to adjusted EBITDA was 5.04× as of March 31, 2026, at the high end of the company's target range, which may limit financial flexibility and increase refinancing risk (https://www.sec.gov/Archives/edgar/data/1492298/000149229826000011/sbraex9922026q1-final.htm).

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SBRA

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Same-store managed senior housing cash NOI increased 17.1% year-over-year in Q2 2025, reflecting substantial operational improvement throughout Sabra’s core properties (Reuters).

Sabra secured a $500 million unsecured term loan in Q2 2025 to refinance $500 million in senior notes, enhancing liquidity and lowering both near-term maturity and interest rate exposure (Reuters).

Analyst sentiment remains positive, with a median 12-month price target of $20.00 implying 8.6% potential upside, and no sell ratings as of Q2, suggesting widespread market confidence (Reuters).

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.